Cyclerion Therapeutics Inc (CYCN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cyclerion Therapeutics Inc (CYCN) has a cash flow conversion efficiency ratio of -0.282x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.43 Million) by net assets ($5.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cyclerion Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
Cyclerion Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Cyclerion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cyclerion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cyclerion Therapeutics Inc ranked by their cash flow conversion efficiency. Explore CYCN cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Income & Growth VCT
LSE:IGV
|
-0.016x |
|
Biophytis S.A.
PA:ALBPS
|
0.472x |
|
CLS Holdings plc
LSE:CLI
|
0.013x |
|
Inventronics Ltd
V:IVX
|
-0.005x |
|
Gibui Holdings Ltd
TA:GIBUI
|
-0.080x |
|
Erayak Power Solution Group Inc. Class A Ordinary Shares
NASDAQ:RAYA
|
-0.068x |
|
Kiplin Metals Inc
V:KIP
|
-0.072x |
|
Catheter Precision Inc.
NYSE MKT:VTAK
|
-0.227x |
Annual Cash Flow Conversion Efficiency for Cyclerion Therapeutics Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Cyclerion Therapeutics Inc from 2016 to 2025. View current stock price of Cyclerion Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.09 Million | $-3.31 Million | -0.365x | +25.50% |
| 2024-12-31 | $8.85 Million | $-4.33 Million | -0.490x | +73.99% |
| 2023-12-31 | $11.29 Million | $-21.25 Million | -1.882x | +51.56% |
| 2022-12-31 | $10.45 Million | $-40.61 Million | -3.885x | -413.35% |
| 2021-12-31 | $48.25 Million | $-36.52 Million | -0.757x | +37.88% |
| 2020-12-31 | $59.49 Million | $-72.49 Million | -1.218x | -16.50% |
| 2019-12-31 | $97.73 Million | $-102.22 Million | -1.046x | -111.20% |
| 2018-12-31 | $-10.45 Million | $-97.50 Million | 9.335x | -1.53% |
| 2017-12-31 | $-8.57 Million | $-81.22 Million | 9.480x | +28.52% |
| 2016-12-31 | $-6.76 Million | $-49.87 Million | 7.377x | -- |
About Cyclerion Therapeutics Inc
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an oral… Read more